High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages

B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction

(2013) Christiane S. Tudor et al.   HUMAN PATHOLOGY

Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma

(2013) Luigi Panico et al.   LEUKEMIA & LYMPHOMA

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

(2012) Y. L. Kasamon et al.   BLOOD

Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome

(2012) Paul Greaves et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment

(2011) Christian Steidl et al.   JOURNAL OF CLINICAL ONCOLOGY

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

(2010) S. M. Castellino et al.   BLOOD

CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes

(2010) B. H. Nelson   JOURNAL OF IMMUNOLOGY

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating clonotypic B cells in classic Hodgkin lymphoma

(2009) R. J. Jones et al.   BLOOD

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

(2008) B. Chetaille et al.   BLOOD

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

(2007) Yasuhiro Oki et al.   CANCER